1. A 48-year-old heart transplant recipient on tacrolimus 4 mg twice daily (most recent trough 9.2 ng/mL, target 8–12 ng/mL) is admitted with invasive Aspergillus tracheobronchitis. Voriconazole is the first-line agent, but the transplant team decides to use itraconazole instead due to concern about voriconazole's neuropsychiatric side effects in this patient who had visual hallucinations during a prior course. Itraconazole oral solution 200 mg twice daily is prescribed. Which of the following management plans is most appropriate for tacrolimus co-administration?
A) Continue tacrolimus at the current dose of 4 mg twice daily and check a trough level in 7 days; itraconazole's interaction with tacrolimus is modest and clinically significant only after 10–14 days of co-administration, providing a safe window for standard monitoring
B) Discontinue tacrolimus entirely for the first 72 hours of itraconazole therapy to prevent supratherapeutic accumulation, then restart at 1 mg twice daily with daily trough monitoring
C) Reduce tacrolimus dose to 3 mg twice daily (a 25% reduction) and check trough in 5 days; itraconazole's CYP3A4 inhibition is moderate in transplant patients and a quarter-dose reduction provides adequate protection against tacrolimus toxicity
D) Reduce tacrolimus dose by 50–75% at the time itraconazole is initiated — for example, from 4 mg twice daily to 1–2 mg twice daily — and check a tacrolimus trough daily from day 1 until a new steady state is confirmed; itraconazole potently inhibits both CYP3A4 and P-glycoprotein simultaneously, which can increase tacrolimus concentrations 5- to 10-fold or more, causing nephrotoxicity, neurotoxicity, and hypertension if the dose is not proactively reduced
E) Switch from oral tacrolimus to IV tacrolimus at half the oral dose; IV administration bypasses the intestinal CYP3A4 and P-glycoprotein inhibition by itraconazole, limiting the interaction to only the hepatic metabolic component and reducing the concentration increase to a manageable 1.5-fold
ANSWER: D
Rationale:
Option D is correct. Tacrolimus is a substrate of both CYP3A4 (cytochrome P450 3A4) and P-glycoprotein (P-gp), which together determine its oral bioavailability and systemic clearance. Itraconazole is a potent inhibitor of both CYP3A4 and P-gp simultaneously: CYP3A4 inhibition reduces first-pass and hepatic metabolism while P-gp inhibition reduces efflux from enterocytes and biliary excretion. The combined dual inhibition can increase tacrolimus blood concentrations 5- to 10-fold or more within days of initiating itraconazole. Tacrolimus has an extremely narrow therapeutic index; concentration increases of this magnitude cause calcineurin inhibitor toxicity including nephrotoxicity, neurotoxicity (tremor, headache, encephalopathy), and hypertension that may not be reversible if onset is delayed. The correct approach is proactive rather than reactive: reduce the tacrolimus dose by 50 to 75% at the time itraconazole is started — not after the fact when toxicity has developed — and monitor trough concentrations daily until a new steady state is confirmed. For this patient, reducing from 4 mg twice daily to 1 to 2 mg twice daily at itraconazole initiation and checking daily troughs is the standard of care.
Option A: Option A is incorrect; there is no safe 7-day window before checking the tacrolimus level. The interaction develops within 24 to 48 hours of initiating itraconazole as enzyme inhibition takes effect, and tacrolimus toxicity can develop rapidly once concentrations rise 5- to 10-fold above baseline.
Option B: Option B is incorrect; discontinuing tacrolimus entirely would risk acute rejection in a heart transplant patient. Tacrolimus should be dose-reduced, not stopped.
Option C: Option C is incorrect; a 25% dose reduction is grossly inadequate given the potential for 5- to 10-fold concentration increases. A 25% reduction would leave the patient with tacrolimus concentrations several-fold above the therapeutic range.
Option E: Option E is incorrect; IV tacrolimus still undergoes hepatic CYP3A4-mediated metabolism and P-gp-mediated biliary efflux; itraconazole inhibits both pathways regardless of route of administration. Switching to IV does not sufficiently limit the interaction.
2. A 38-year-old man with HIV (human immunodeficiency virus) and a CD4 count of 42 cells/mcL is hospitalized with odynophagia and endoscopy-confirmed esophageal candidiasis. He is started on fluconazole 200 mg IV daily. After 3 days he is improving, tolerating liquids, and is afebrile. The medical team plans to discharge him on oral therapy. Which statement best describes the appropriate oral fluconazole conversion and the pharmacokinetic rationale?
A) Switch to oral fluconazole 400 mg daily — double the IV dose — because oral bioavailability in immunocompromised patients with esophageal candidiasis is reduced to approximately 50% due to mucosal inflammation impairing intestinal absorption
B) Switch to oral fluconazole 200 mg daily — the same dose as the IV regimen — because fluconazole oral bioavailability is approximately 90% and is not significantly affected by food, gastric pH, acid-suppressing medications, or mucosal inflammation, making dose-for-dose IV-to-oral conversion pharmacokinetically reliable
C) Switch to itraconazole oral solution 200 mg twice daily because it has a broader antifungal spectrum than fluconazole and is preferred over fluconazole for esophageal candidiasis step-down in HIV-positive patients with low CD4 counts
D) Switch to fluconazole oral suspension rather than tablet because tablet formulations have significantly reduced absorption in patients with esophageal mucosal disease and low CD4 counts; the suspension achieves more predictable plasma concentrations in this clinical context
E) Reduce the oral fluconazole dose to 150 mg daily because the prolonged half-life of fluconazole in HIV-positive patients due to reduced hepatic CYP metabolism results in drug accumulation with the standard 200 mg dose
ANSWER: B
Rationale:
Option B is correct. Fluconazole has oral bioavailability of approximately 90% — one of the highest among systemic antifungals — and this absorption is not meaningfully affected by food intake, gastric pH, acid suppression, or the degree of esophageal mucosal inflammation. Unlike itraconazole capsules, which require gastric acid and bile for dissolution, fluconazole is absorbed by passive diffusion in the small intestine with minimal dependence on luminal conditions. This property makes IV-to-oral conversion at the identical dose pharmacokinetically reliable and straightforward; patients can be transitioned from IV to oral fluconazole as soon as they can tolerate oral intake, with confidence that plasma concentrations will be equivalent. This approach is cost-effective, supports early discharge, and is endorsed by IDSA guidelines for esophageal candidiasis management.
Option A: Option A is incorrect; there is no pharmacokinetic basis for doubling the oral dose in this patient. Fluconazole oral bioavailability is not reduced to 50% in immunocompromised patients or in the presence of esophageal mucosal inflammation. IV-to-oral conversion at the same dose is the correct approach.
Option C: Option C is incorrect; itraconazole is not preferred over fluconazole for esophageal candidiasis. Fluconazole is the first-line agent for esophageal candidiasis per IDSA guidelines and is the appropriate step-down agent after IV fluconazole induction.
Option D: Option D is incorrect; there is no pharmacokinetic evidence that oral fluconazole tablets are less well absorbed than suspension in patients with esophageal mucosal disease. Both formulations achieve equivalent plasma concentrations in the clinical dose range; this distinction does not drive prescribing decisions.
Option E: Option E is incorrect; fluconazole half-life is not systematically prolonged in HIV-positive patients due to reduced hepatic CYP metabolism. Fluconazole clearance is primarily renal, not CYP-dependent; unless this patient has significant renal impairment, no dose reduction is warranted.
3. A 61-year-old woman with acute myeloid leukemia (AML) undergoing induction chemotherapy has been receiving fluconazole 400 mg daily as antifungal prophylaxis for 28 days. She develops fever unresponsive to broad-spectrum antibiotics and blood cultures grow Candida glabrata (now reclassified as Nakaseomyces glabratae). Susceptibility results are pending. The hematology fellow proposes continuing fluconazole at 800 mg daily while awaiting susceptibility data. Which response most accurately addresses this proposal and the underlying resistance pharmacology?
A) The proposal is reasonable; Candida glabrata susceptibility-dose-dependent (SDD) profiles indicate that doubling the fluconazole dose to 800 mg daily is sufficient to overcome azole resistance in breakthrough candidemia and is equivalent to echinocandin therapy in clinical outcome studies
B) The proposal is reasonable only if the patient's CrCl (creatinine clearance) is above 50 mL/min; in patients with adequate renal function, 800 mg daily fluconazole achieves plasma concentrations above the SDD breakpoint for C. glabrata and is an acceptable empirical strategy
C) The proposal should be rejected; Candida glabrata has intrinsic fluconazole resistance identical to Candida krusei, making fluconazole contraindicated at any dose for all C. glabrata infections regardless of susceptibility testing results
D) The proposal is acceptable as short-term empirical therapy for up to 72 hours while awaiting formal susceptibility testing; after 72 hours, fluconazole should be continued only if susceptibility testing confirms an MIC (minimum inhibitory concentration) below 8 mcg/mL
E) The proposal should be rejected; breakthrough candidemia developing during fluconazole prophylaxis substantially enriches the probability of a fluconazole-resistant isolate — CDR1 (Candida Drug Resistance 1) and CDR2 (Candida Drug Resistance 2) efflux pump upregulation is the predominant mechanism and confers cross-resistance that cannot be overcome by dose escalation — and an echinocandin should be initiated empirically while susceptibility results are awaited
ANSWER: E
Rationale:
Option E is correct. Candida glabrata harbors fluconazole resistance in 10 to 30% of isolates in many centers under baseline conditions, but breakthrough candidemia developing during azole prophylaxis substantially enriches this proportion — prior azole exposure selects for CDR1 and CDR2 upregulation, which is driven by gain-of-function mutations in the TAC1 transcription factor gene. CDR1 and CDR2 are ABC (adenosine triphosphate-binding cassette) efflux transporters that actively pump all azole class members out of the fungal cell; the mechanism is not saturable by dose escalation within clinically achievable concentration ranges. An MIC of 64 mcg/mL or above — common in CDR-overexpressing isolates — is far above achievable fluconazole plasma concentrations at any approved dose. Escalating to 800 mg daily in a patient who developed breakthrough infection on 400 mg daily provides no mechanistic rationale for success and delays initiation of effective therapy. Current IDSA guidelines recommend empirical echinocandin therapy for all C. glabrata candidemia, with step-down to fluconazole reserved only for clinically stable patients with confirmed susceptible isolates and negative follow-up blood cultures.
Option A: Option A is incorrect; dose doubling is not equivalent to echinocandin therapy in C. glabrata breakthrough candidemia. No clinical outcome study supports fluconazole dose escalation as a substitute for echinocandin therapy in this setting, and the resistance mechanism renders dose escalation pharmacologically ineffective for CDR-overexpressing isolates.
Option B: Option B is incorrect; the appropriateness of 800 mg fluconazole in this scenario does not depend on renal function — the problem is the resistance mechanism, not drug clearance. Regardless of CrCl, escalating fluconazole in a patient with breakthrough candidemia on fluconazole prophylaxis is not appropriate empirical management.
Option C: Option C is incorrect; Candida glabrata does not have intrinsic fluconazole resistance. Its resistance is variable and partly acquired; a proportion of isolates remain susceptible. It is not pharmacologically equivalent to C. krusei, which has universally intrinsic fluconazole resistance.
Option D: Option D is incorrect; there is no evidence-based 72-hour window during which fluconazole escalation is safe in this scenario. The patient has a blood-culture-positive candidemia and an active infection; delaying effective echinocandin therapy for 72 hours waiting for susceptibility data exposes her to inadequately treated candidemia.
4. A 55-year-old woman with autoimmune gastritis and confirmed achlorhydria (serum gastrin 940 pg/mL, absent acid on pH testing) is diagnosed with blastomycosis of the lung and skin. She is prescribed itraconazole capsules 200 mg twice daily. At a two-week follow-up visit, her skin lesions are unchanged and a steady-state itraconazole trough level returns as less than 0.1 mcg/mL. She reports taking the capsules with her meals as instructed. What is the most appropriate next step?
A) Switch to itraconazole oral solution 200 mg twice daily and instruct the patient to take it on an empty stomach at least one hour before meals; the oral solution's hydroxypropyl-beta-cyclodextrin vehicle pre-solubilizes the drug independent of gastric acid, providing bioavailability far less dependent on intragastric pH; recheck a combined itraconazole plus hydroxy-itraconazole trough at steady state in 14 days targeting above 1.0 mcg/mL
B) Double the itraconazole capsule dose to 400 mg twice daily with meals; the undetectable trough reflects subtherapeutic dosing rather than a formulation-related absorption failure, and doubling the dose will achieve therapeutic concentrations despite achlorhydria
C) Switch to itraconazole capsules administered with 240 mL of cola or another acidic beverage on an empty stomach; the acidic beverage temporarily lowers intraluminal pH sufficiently to allow capsule dissolution and drug release in achlorhydric patients
D) Switch to fluconazole 400 mg daily as it is unaffected by gastric pH; fluconazole has equivalent antifungal activity to itraconazole against Blastomyces dermatitidis and is the guideline-preferred alternative for blastomycosis when itraconazole cannot be absorbed
E) Add omeprazole 40 mg daily to the regimen; stimulating gastrin-independent acid secretion through proton pump activation will restore gastric acidity in achlorhydric patients and allow itraconazole capsule dissolution to proceed normally
ANSWER: A
Rationale:
Option A is correct. The undetectable itraconazole trough directly results from itraconazole capsule dissolution failure in this achlorhydric patient. Capsule dissolution requires an acidic intragastric environment (pH below approximately 3 to 4) to solubilize the lipophilic itraconazole from its sugar-sphere coating; with achlorhydria, this environment is absent and bioavailability falls to near zero even with perfect adherence and food co-administration. The correct solution is switching to the itraconazole oral solution, which uses hydroxypropyl-beta-cyclodextrin as a solubilizing vehicle that keeps itraconazole in a pre-solubilized state independent of gastric pH. The oral solution should be administered on an empty stomach (fasting state) — the opposite of the capsule instruction — because food and bile can compete with cyclodextrin for lipophilic drug binding in the intestinal lumen, reducing cyclodextrin-facilitated absorption. A repeat trough at steady state (14 days after switching) targeting a combined itraconazole plus hydroxy-itraconazole trough above 1.0 mcg/mL confirms therapeutic exposure.
Option B: Option B is incorrect; doubling the capsule dose will not overcome the fundamental formulation failure. In the absence of gastric acid, itraconazole capsule dissolution remains essentially zero regardless of dose; 400 mg of undissolved drug does not improve upon 200 mg of undissolved drug.
Option C: Option C is incorrect; while using acidic beverages to improve capsule absorption has been described in patients with acid suppression, this approach is unreliable in achlorhydria because the patient lacks intrinsic acid-producing capacity and the cola's buffering capacity in the stomach is insufficient to predictably achieve the sustained acidic pH required for consistent capsule dissolution. Switching to the oral solution is the evidence-based standard.
Option D: Option D is incorrect; fluconazole is not equivalent to itraconazole for blastomycosis. Itraconazole is the first-line agent for non-CNS, non-severe blastomycosis per IDSA guidelines; fluconazole has inferior activity against Blastomyces dermatitidis and is not the preferred alternative.
Option E: Option E is incorrect; proton pump inhibitors such as omeprazole suppress acid secretion — they do not stimulate it. Omeprazole would further elevate intragastric pH, making capsule dissolution even worse. Achlorhydria from autoimmune gastritis reflects loss of parietal cells; PPIs have no role in restoring gastric acid in this setting.
5. A 67-year-old man with stage 4 chronic kidney disease (CKD) — CrCl (creatinine clearance) estimated at 22 mL/min by CKD-EPI equation — completes two weeks of liposomal amphotericin B induction for cryptococcal meningitis. Blood and CSF (cerebrospinal fluid) cultures are now sterile and the patient is clinically stable. The team plans to transition to fluconazole consolidation. Standard consolidation dosing for cryptococcal meningitis is fluconazole 400 mg daily for 8 weeks. Which dosing strategy is most appropriate for this patient?
A) Use the standard 400 mg daily dose without adjustment; fluconazole dose modification is only required when CrCl falls below 10 mL/min, and a CrCl of 22 mL/min is above the threshold requiring dose change
B) Start fluconazole 200 mg daily from day 1 without a loading dose; in CKD stage 4 the risk of supratherapeutic peak concentrations from a full loading dose outweighs the benefit of rapid therapeutic level achievement in a non-acute step-down scenario
C) Give a full loading dose of fluconazole 400 mg on day 1 to rapidly achieve therapeutic CSF (cerebrospinal fluid) concentrations, then reduce the maintenance dose to 200 mg daily (50% of standard) for the remainder of the consolidation course; approximately 80% of fluconazole is excreted unchanged in urine and CrCl of 22 mL/min substantially prolongs the half-life, necessitating maintenance dose reduction to prevent drug accumulation
D) Give fluconazole 400 mg every 48 hours (dosing interval doubled) rather than 200 mg daily; interval extension achieves the same time-averaged plasma concentration as 200 mg daily but results in lower trough concentrations that reduce QTc prolongation risk in the setting of CKD
E) Avoid fluconazole entirely in CKD stage 4 and use voriconazole 200 mg twice daily instead; voriconazole is hepatically metabolized and requires no renal dose adjustment, making it preferable to fluconazole in patients with significantly impaired renal function
ANSWER: C
Rationale:
Option C is correct. Fluconazole is excreted approximately 80% as unchanged parent drug in the urine; renal clearance is therefore the primary determinant of its elimination half-life and steady-state concentrations. In a patient with CrCl of 22 mL/min (well below the 50 mL/min threshold at which dose adjustment is recommended), fluconazole half-life is substantially prolonged — from the normal 27 to 37 hours to potentially 80 hours or more — and standard maintenance dosing would cause progressive drug accumulation and concentration-dependent toxicity including QTc prolongation. The recommended approach is to give the full loading dose unchanged on day 1: the loading dose is a single administration whose peak concentration is determined by volume of distribution and the dose given, not by clearance rate; preserving the full loading dose ensures rapid achievement of therapeutic CSF concentrations critical for ongoing CNS protection against cryptococcal relapse. The maintenance dose is then reduced to 50% of standard (200 mg daily for the standard 400 mg regimen) to prevent accumulation between doses. This two-component strategy — full load, reduced maintenance — is the pharmacokinetically correct approach to renally cleared drugs in renal impairment.
Option A: Option A is incorrect; dose adjustment is recommended for CrCl below 50 mL/min, not only below 10 mL/min. A CrCl of 22 mL/min requires the 50% maintenance dose reduction; continuing 400 mg daily would cause progressive accumulation.
Option B: Option B is incorrect; omitting the loading dose is pharmacokinetically unjustified and clinically counterproductive. The loading dose rapidly achieves therapeutic concentrations; without it, reaching steady state on 200 mg daily in a patient with a prolonged half-life could take many days, leaving the CNS without adequate antifungal protection during that period.
Option D: Option D is incorrect; while interval doubling is sometimes used for renally cleared drugs, the standard fluconazole recommendation in severe non-dialysis CKD is 50% dose reduction at the same once-daily interval, not interval extension. Furthermore, achieving lower trough concentrations is not the goal for a fungistatic drug requiring continuous exposure; adequate trough concentrations are needed for efficacy.
Option E: Option E is incorrect; voriconazole is not preferred over fluconazole for cryptococcal meningitis consolidation in CKD. Voriconazole has limited evidence for cryptococcal disease and is not guideline-recommended for this indication. Additionally, voriconazole's IV formulation uses a cyclodextrin vehicle that accumulates in renal failure, and the oral formulation has its own interaction and monitoring complexities that do not simplify management.
6. A 52-year-old woman with relapsed acute myeloid leukemia (AML) is receiving salvage chemotherapy and has been on fluconazole prophylaxis for 3 weeks. She develops fever, rigors, and hypotension. Two sets of blood cultures drawn 20 minutes apart both grow yeast. The organism is identified as Candida krusei. The microbiology laboratory reports a fluconazole MIC of 16 mcg/mL and marks the susceptibility result as "susceptible-dose-dependent (SDD)." The covering resident proposes treating with high-dose fluconazole 800 mg IV daily given the SDD result. What is the most appropriate response to this proposal?
A) Accept the proposal; the SDD designation indicates that with a pharmacokinetic/pharmacodynamic (PK/PD) target attainment analysis confirming fluconazole AUC/MIC (area under the curve to minimum inhibitory concentration) ratio above 25, 800 mg daily is expected to be therapeutically effective against this isolate
B) Accept the proposal with one modification: add flucytosine 25 mg/kg every 6 hours as synergistic combination therapy; the combination of high-dose fluconazole plus flucytosine overcomes C. krusei's azole resistance through a complementary mechanism of fungal DNA disruption
C) Reject the proposal; C. krusei is intrinsically resistant to fluconazole and the SDD result should be disregarded — request echinocandin therapy as the appropriate first-line agent for C. krusei candidemia
D) Reject the proposal; Candida krusei has intrinsic fluconazole resistance present in all isolates, arising from constitutively low CYP51 affinity for fluconazole combined with CDR (Candida Drug Resistance) efflux expression — the SDD laboratory result is unreliable for this species and fluconazole should never be used to treat C. krusei infection regardless of MIC value or susceptibility report; initiate an echinocandin promptly
E) Accept the proposal temporarily as a bridge for 48 hours while repeat cultures are confirmed; if the organism is definitively identified as C. krusei by a second method, switch to an echinocandin at that point — the 48-hour delay for confirmation is clinically safe in a hemodynamically stable patient
ANSWER: D
Rationale:
Option D is correct. Candida krusei (now reclassified as Pichia kudriavzevii) has intrinsic fluconazole resistance — resistance that is present in every clinical isolate, is not acquired through prior antifungal exposure, and cannot be overcome by dose escalation. The mechanism combines constitutively low intrinsic affinity of the C. krusei CYP51 enzyme for fluconazole with constitutive expression of CDR efflux transporters. Because the resistance is intrinsic and mechanistic, in vitro susceptibility testing results for fluconazole in C. krusei are unreliable guides to clinical treatment; a "susceptible-dose-dependent" result is an artifact of the testing methodology and does not reflect achievable clinical outcomes. Species-level prediction of intrinsic resistance supersedes MIC-based susceptibility interpretation for this species. Current IDSA guidelines explicitly state that fluconazole should not be used for C. krusei infections regardless of MIC or susceptibility test result. Echinocandins (caspofungin, micafungin, anidulafungin) are first-line for invasive C. krusei infections; this patient is bacteremic, febrile, and hypotensive and requires prompt initiation of effective antifungal therapy.
Option A: Option A is incorrect; PK/PD target attainment analysis does not override the species-level intrinsic resistance classification for C. krusei. The concept of AUC/MIC targeting applies to organisms where MICs reflect genuine susceptibility; for C. krusei, the MIC does not predict clinical response to fluconazole.
Option B: Option B is incorrect; flucytosine combined with fluconazole has no established role in C. krusei candidemia. The intrinsic fluconazole resistance of C. krusei cannot be circumvented by adding flucytosine, which acts through a distinct mechanism (fungal DNA disruption after intracellular conversion) and does not compensate for the inactive azole partner.
Option C: Option C is incorrect as a complete answer; while it reaches the right conclusion (reject the proposal, use echinocandin), it incompletely explains the intrinsic resistance mechanism and fails to address the flawed SDD interpretation — Option D provides the complete and precise clinical explanation required here.
Option E: Option E is incorrect; a 48-hour delay for "confirmation" is not clinically acceptable when the organism has already been identified as C. krusei. This patient is hypotensive and bacteremic; delay in starting effective antifungal therapy while continuing an ineffective agent risks morbidity and mortality from untreated candidemia.
7. A 66-year-old man with a history of myocardial infarction is maintained on simvastatin 40 mg nightly, aspirin, and metoprolol. He develops histoplasmosis involving the lungs and skin and is started on itraconazole oral solution 200 mg twice daily. After 3 weeks, he presents to the emergency department with severe bilateral thigh pain, dark urine, and markedly elevated creatine kinase (CK) at 48,000 U/L. Serum creatinine has risen from baseline 1.1 to 2.9 mg/dL. What pharmacokinetic interaction most directly accounts for this presentation, and what statin should replace simvastatin going forward?
A) Itraconazole inhibits CYP2C9 (cytochrome P450 2C9), the primary enzyme responsible for simvastatin metabolism; CYP2C9 inhibition raised simvastatin acid concentrations sufficiently to cause statin myopathy; switch to atorvastatin, which is not a CYP2C9 substrate and is unaffected by itraconazole
B) Itraconazole is a potent inhibitor of CYP3A4 (cytochrome P450 3A4) and P-glycoprotein; simvastatin and its active acid form are CYP3A4-metabolized substrates — co-administration with itraconazole can increase simvastatin acid plasma exposure by 10- to 19-fold, causing skeletal muscle toxicity and rhabdomyolysis; the combination is contraindicated and simvastatin should be replaced with pravastatin or rosuvastatin, which are minimally dependent on CYP3A4 for elimination
C) Itraconazole inhibits the renal organic anion transporter OAT3 (organic anion transporter 3), reducing simvastatin renal clearance and causing simvastatin acid accumulation; switch to fluvastatin, which is eliminated exclusively by biliary excretion and is unaffected by renal transporter inhibition
D) Itraconazole directly inhibits HMG-CoA reductase in skeletal muscle, producing an additive pharmacodynamic effect with simvastatin that overwhelms the therapeutic window; the combination is synergistically myotoxic regardless of the statin used, and all statins are contraindicated with itraconazole
E) Itraconazole causes rhabdomyolysis through a direct mitochondrial toxicity mechanism independent of any pharmacokinetic interaction with simvastatin; the elevated CK reflects itraconazole's own skeletal muscle toxicity profile, and simvastatin can be continued after the acute episode resolves
ANSWER: B
Rationale:
Option B is correct. Simvastatin and its active form simvastatin acid are primarily metabolized by CYP3A4 in the intestinal wall and liver. Itraconazole is a potent inhibitor of both CYP3A4 and P-glycoprotein; co-administration substantially reduces first-pass and systemic simvastatin metabolism while also increasing oral bioavailability by inhibiting intestinal P-gp efflux. Clinical pharmacokinetic studies have documented simvastatin acid exposure increases of 10- to 19-fold during itraconazole co-administration — concentrations far above the myotoxicity threshold. This combination is formally contraindicated in itraconazole prescribing information. The patient's presentation — severe bilateral myalgia, CK of 48,000 U/L, and acute kidney injury (rhabdomyolysis-induced pigment nephropathy) — is a direct consequence of this interaction. Management requires immediate discontinuation of simvastatin, aggressive IV hydration, and monitoring of renal function. For long-term cardiac risk management, the patient should be switched to a statin that is not significantly metabolized by CYP3A4: pravastatin is primarily renally eliminated with minimal CYP metabolism, and rosuvastatin is metabolized primarily by CYP2C9 with minimal CYP3A4 involvement — both are appropriate alternatives during itraconazole therapy.
Option A: Option A is incorrect; simvastatin is not primarily metabolized by CYP2C9, and itraconazole does not significantly inhibit CYP2C9. Atorvastatin is a CYP3A4 substrate and would also be affected by itraconazole CYP3A4 inhibition, making it an inappropriate substitute in this context.
Option C: Option C is incorrect; simvastatin is not primarily renally cleared or dependent on OAT3. Its metabolism is hepatic CYP3A4-dependent, and fluvastatin (a CYP2C9 substrate) would actually be more affected by fluconazole than by itraconazole; the proposed mechanism is pharmacologically inaccurate.
Option D: Option D is incorrect; itraconazole does not directly inhibit HMG-CoA reductase. The toxicity in this case is pharmacokinetically mediated through elevated simvastatin concentrations, not pharmacodynamic synergy on the enzyme target. Not all statins are contraindicated with itraconazole — statins with minimal CYP3A4 dependence are safe alternatives.
Option E: Option E is incorrect; itraconazole does not cause clinically significant rhabdomyolysis as a direct drug effect independent of statin co-administration. The rhabdomyolysis in this case is entirely explained by the CYP3A4-mediated simvastatin toxicity.
8. A 78-year-old woman with atrial fibrillation on stable warfarin (INR 2.1 for the past three months, target 2.0–3.0) is started on fluconazole 200 mg daily for vulvovaginal candidiasis by her primary care physician, who does not check for drug interactions. Five days later she presents to the emergency department with a spontaneous right forearm hematoma. Her INR is 7.4. She has no new medications, dietary changes, or illness. Which explanation best accounts for the INR elevation, and what is the most appropriate immediate management?
A) Fluconazole inhibited CYP3A4, blocking R-warfarin metabolism; R-warfarin is the more pharmacologically active enantiomer and its accumulation drove the INR elevation; reverse with vitamin K 10 mg IV and fresh frozen plasma, and hold fluconazole permanently given the patient's age and bleeding risk
B) Fluconazole displaced warfarin from plasma albumin binding sites, acutely raising the free warfarin fraction to supratherapeutic levels; manage with temporary warfarin dose reduction to 50% and recheck INR in 48 hours; no fluconazole discontinuation is required as the effect is transient
C) Fluconazole inhibited intestinal P-glycoprotein, doubling warfarin oral bioavailability from approximately 50% to near 100%; manage by switching to a parenteral anticoagulant for the duration of fluconazole therapy and resuming warfarin at half the previous dose once fluconazole is completed
D) The INR elevation is coincidental and unrelated to fluconazole; the most likely cause is a dietary change in vitamin K intake that the patient has not recognized; resume warfarin at the prior stable dose after INR correction with vitamin K 2.5 mg orally
E) Fluconazole potently inhibited CYP2C9 (cytochrome P450 2C9), the enzyme responsible for metabolism of S-warfarin — the more pharmacologically active enantiomer with approximately 3 to 5 times greater anticoagulant potency than R-warfarin; S-warfarin accumulation drove the INR from 2.1 to 7.4 within five days; immediate management includes holding warfarin, giving vitamin K 2.5–5 mg orally or IV depending on bleeding severity, and close INR monitoring; when anticoagulation is resumed, warfarin will require dose reduction and the fluconazole course should be completed with daily INR checks and warfarin dose titration
ANSWER: E
Rationale:
Option E is correct. This case is a classic presentation of the fluconazole-warfarin pharmacokinetic interaction. Fluconazole is a potent inhibitor of CYP2C9 (cytochrome P450 2C9), the enzyme primarily responsible for 7-hydroxylation of S-warfarin. S-warfarin is the more pharmacologically active enantiomer, with approximately three to five times greater VKORC1 (vitamin K epoxide reductase complex 1) inhibitory potency than R-warfarin. Fluconazole inhibition of CYP2C9 substantially reduces S-warfarin clearance; plasma S-warfarin concentrations rise and the INR increases 2- to 3-fold within three to five days — the timeline seen here (five days, INR 2.1 to 7.4). The spontaneous hematoma is a direct consequence of supratherapeutic anticoagulation. Immediate management: hold warfarin, administer vitamin K (oral 2.5 to 5 mg for non-life-threatening bleeding; IV for severe or life-threatening hemorrhage), and monitor INR every 6 to 12 hours until in safe range. Fluconazole can be continued to complete the antifungal course with daily INR monitoring and warfarin dose reduction — typically 25 to 50% — once anticoagulation is resumed.
Option A: Option A is incorrect; R-warfarin (not S-warfarin) is the less pharmacologically active enantiomer and is primarily metabolized by CYP1A2 and CYP3A4. Fluconazole's moderate CYP3A4 inhibition does affect R-warfarin to some degree but is not the primary driver. Fresh frozen plasma is indicated for life-threatening or surgical bleeding, not a forearm hematoma; this represents an overly aggressive reversal strategy for the clinical scenario.
Option B: Option B is incorrect; protein binding displacement does not produce sustained, large INR increases of this magnitude. Displacement is a transient pharmacokinetic phenomenon; the sustained CYP2C9 inhibition by fluconazole is the mechanism here, not albumin displacement.
Option C: Option C is incorrect; warfarin oral bioavailability is already approximately 93 to 100%, not 50%. Fluconazole does not significantly inhibit intestinal P-glycoprotein for warfarin. The mechanism is hepatic CYP2C9 metabolic inhibition, not absorption enhancement.
Option D: Option D is incorrect; a fluconazole-induced INR rise of this magnitude occurring five days after starting the drug in a previously stable patient is not coincidental. The mechanism is well-established and the temporal relationship is highly characteristic of CYP2C9 inhibition; dietary vitamin K change as the primary explanation is not supported.
9. A 69-year-old retired farmer from Missouri presents with three weeks of fever, weight loss, fatigue, and progressive dyspnea. Workup reveals bilateral pulmonary infiltrates, hepatosplenomegaly, serum Histoplasma antigen of 14.2 ng/mL, and urine antigen positive. Echocardiogram shows ischemic cardiomyopathy with ejection fraction (EF) of 24% and dilated left ventricle. He is clinically moderately ill but not in respiratory failure or shock. The infectious disease consultant recommends antifungal treatment. The team asks whether itraconazole can be initiated as primary oral therapy. Which treatment plan is most appropriate?
A) Itraconazole oral solution 200 mg three times daily for the first 3 days (loading), then 200 mg twice daily; in patients with EF above 20%, the negative inotropic effect of itraconazole is subclinical and the benefit of treatment outweighs the theoretical cardiac risk; weekly echocardiography is sufficient monitoring
B) Fluconazole 400 mg daily is the preferred first-line agent for disseminated histoplasmosis in patients with cardiac dysfunction; it has equivalent efficacy to itraconazole, no negative inotropic effects, and is the IDSA-recommended cardiac-safe alternative for this indication
C) Initiate liposomal amphotericin B 3 mg/kg daily for induction (typically 1–2 weeks for moderately severe disease) followed by itraconazole step-down only after clinical stabilization — however, given this patient's ventricular dysfunction with EF of 24%, itraconazole remains formally contraindicated for step-down as well; voriconazole or extended amphotericin B followed by infectious disease-guided alternative azole selection should be considered
D) Itraconazole is safe in this patient because the FDA (Food and Drug Administration) contraindication for ventricular dysfunction applies only to patients receiving itraconazole for onychomycosis; for life-threatening systemic fungal infections, the contraindication is superseded by clinical necessity and itraconazole should be initiated at standard doses
E) Initiate caspofungin 70 mg loading dose then 50 mg daily; echinocandins have established efficacy for disseminated histoplasmosis equivalent to amphotericin B, have no cardiac contraindications, and are the preferred agents for moderately severe disease in patients with heart failure
ANSWER: C
Rationale:
Option C is correct. Itraconazole is formally contraindicated by FDA labeling in patients with evidence of ventricular dysfunction, including congestive heart failure or a history of heart failure, due to its documented negative inotropic effect on the myocardium. This contraindication applies regardless of the antifungal indication — the FDA label does not restrict the contraindication to onychomycosis or any particular indication. With an EF of 24% and dilated cardiomyopathy, this patient has severe ventricular dysfunction and meets the formal contraindication criteria. For moderately severe disseminated histoplasmosis, IDSA guidelines recommend liposomal amphotericin B for induction, which remains appropriate despite CKD or cardiac comorbidity (with renal monitoring). The step-down dilemma is real: itraconazole remains contraindicated for step-down in this patient. Options include extended amphotericin B consolidation, voriconazole (which has been used in limited case reports for histoplasmosis as an itraconazole substitute), or infectious disease consultation to weigh risks and alternatives.
Option A: Option A is incorrect; the FDA contraindication for itraconazole in ventricular dysfunction does not have an EF threshold of 20% — it applies broadly to patients with evidence of ventricular dysfunction, and EF 24% clearly meets this criterion. Weekly echocardiography monitoring does not make itraconazole safe to use in a contraindicated patient.
Option B: Option B is incorrect; fluconazole is not the IDSA-recommended first-line agent or the preferred cardiac-safe alternative for disseminated histoplasmosis. Fluconazole has inferior activity against Histoplasma capsulatum compared to itraconazole and is considered a second- or third-line option, not a routine substitute.
Option D: Option D is incorrect; the FDA contraindication for itraconazole in ventricular dysfunction is not restricted to the onychomycosis indication. The prescribing information states the contraindication for patients with evidence of ventricular dysfunction without indication-specific qualification. The clinical necessity of antifungal therapy does not legally or pharmacologically override a formal FDA contraindication.
Option E: Option E is incorrect; echinocandins do not have established efficacy for disseminated histoplasmosis. Histoplasma capsulatum has intrinsic resistance to echinocandins because its cell wall beta-glucan structure and glucan synthase are not susceptible to echinocandin inhibition in the same way as Candida species.
10. A 29-year-old man with HIV (human immunodeficiency virus) and a CD4 count of 38 cells/mcL is receiving rifampin, isoniazid, pyrazinamide, and ethambutol for smear-positive pulmonary tuberculosis diagnosed 6 weeks ago. He now develops progressive fatigue, weight loss, fevers, and pancytopenia. Bone marrow biopsy reveals intracellular yeast consistent with Histoplasma capsulatum. Serum and urine Histoplasma antigens are markedly positive. The team initiates itraconazole oral solution 200 mg twice daily while continuing the TB regimen. At a 14-day follow-up, the patient remains febrile, antigenemia is unchanged, and itraconazole trough is undetectable. Which of the following most accurately explains this failure and identifies the most appropriate corrective action?
A) Rifampin is a potent inducer of CYP3A4 (cytochrome P450 3A4) through activation of the pregnane X receptor (PXR), dramatically increasing both intestinal and hepatic CYP3A4 expression; because itraconazole is primarily metabolized by CYP3A4, rifampin reduces itraconazole plasma concentrations to near zero regardless of dose, making the combination essentially contraindicated; the correct approach is to treat histoplasmosis with liposomal amphotericin B induction and, in consultation with infectious disease and HIV specialists, consider a rifampin-sparing TB regimen (e.g., replacing rifampin with rifabutin) to allow eventual itraconazole step-down
B) The undetectable trough reflects a drug formulation error; itraconazole oral solution should have been prescribed as itraconazole capsules taken with food when co-administered with rifampin, because the capsule formulation's slower gastric release delays the drug from reaching the intestinal CYP3A4 site and partially mitigates the induction effect
C) Rifampin inhibits intestinal P-glycoprotein expression specifically in HIV-positive patients, reducing itraconazole absorption to negligible levels; switching to IV itraconazole would completely bypass this interaction and achieve therapeutic plasma concentrations despite continued rifampin co-administration
D) The undetectable trough is due to non-adherence; itraconazole oral solution has an unpleasant taste that frequently causes patients to spit it out rather than swallow it; the solution should be switched to itraconazole capsules and the patient counseled about the importance of completing the full dose with each administration
E) Rifampin and itraconazole compete for CYP3A4 binding sites in a mutually inhibitory manner; itraconazole levels are undetectable because rifampin's competitive CYP3A4 inhibition paradoxically accelerates itraconazole's own self-inhibitory metabolism; reducing the rifampin dose by 50% will restore the pharmacokinetic balance and allow therapeutic itraconazole concentrations to develop within 72 hours
ANSWER: A
Rationale:
Option A is correct. Rifampin is among the most potent CYP3A4 inducers in clinical pharmacology. It activates the pregnane X receptor (PXR), a nuclear receptor that transcriptionally upregulates CYP3A4 in both intestinal enterocytes and hepatocytes. Because itraconazole is primarily metabolized by CYP3A4, rifampin-induced enzyme upregulation accelerates both first-pass intestinal metabolism (reducing oral bioavailability) and systemic hepatic clearance simultaneously. The combined effect reduces itraconazole plasma concentrations to near zero — consistent with the undetectable trough here. This is a well-documented and severe pharmacokinetic interaction. No dose escalation of itraconazole reliably overcomes full-dose rifampin induction. The correct clinical response is to stop itraconazole (which is not working), initiate liposomal amphotericin B for histoplasmosis induction (which is not affected by rifampin), and work with infectious disease and HIV specialists to determine whether rifampin can be replaced with rifabutin — a less potent CYP3A4 inducer — to allow eventual itraconazole step-down once the patient improves.
Option B: Option B is incorrect; itraconazole capsules are not protected from CYP3A4 induction by a slower gastric release mechanism. CYP3A4 induction by rifampin is a sustained transcriptional process affecting the entire intestinal and hepatic CYP3A4 pool; the rate of gastric emptying does not meaningfully mitigate this effect.
Option C: Option C is incorrect; rifampin induces P-glycoprotein expression (rather than inhibiting it), which would further reduce itraconazole absorption. Additionally, while IV itraconazole bypasses first-pass intestinal metabolism, rifampin also substantially induces hepatic CYP3A4, accelerating systemic itraconazole clearance — IV delivery does not resolve the interaction.
Option D: Option D is incorrect; while taste issues with itraconazole oral solution are real, attributing an undetectable trough in a patient with a confirmed severe pharmacokinetic drug interaction to non-adherence without investigating the known rifampin-itraconazole interaction is clinically incorrect. The itraconazole-rifampin interaction is a pharmacokinetically established mechanism that should be addressed directly.
Option E: Option E is incorrect; rifampin is a CYP3A4 inducer, not an inhibitor, and does not compete with itraconazole for CYP3A4 binding sites in a mutually inhibitory manner. Inducing CYP3A4 expression increases metabolic capacity; it does not create a competitive inhibition effect. Reducing the rifampin dose by 50% would not achieve the described pharmacokinetic balance.
11. A 74-year-old man has been in the surgical ICU (intensive care unit) for 18 days following emergency colectomy for perforated diverticulitis. He has a central venous catheter, urinary catheter, and has received multiple courses of broad-spectrum antibiotics. He develops new fever and hypotension, and blood cultures from two separate sites grow yeast. The organism is identified by the laboratory as Candida auris using MALDI-TOF (matrix-assisted laser desorption/ionization time-of-flight) mass spectrometry. The team asks whether to start fluconazole empirically while awaiting susceptibility results. Which response most accurately addresses this question, distinguishing C. auris from the other azole-resistant Candida species discussed in this chapter?
A) Start fluconazole 800 mg IV daily empirically; Candida auris has the same resistance pattern as Candida glabrata — variable fluconazole resistance with 10 to 30% of isolates resistant — and dose escalation to 800 mg daily is appropriate empirical management while susceptibility results are awaited
B) Start fluconazole 400 mg IV daily empirically; while Candida auris has some degree of azole resistance, it retains reliable susceptibility to fluconazole in patients without prior azole exposure, and susceptibility testing results for azoles are not needed before initiating empirical therapy in the ICU setting
C) Start fluconazole 400 mg IV daily and add echinocandin therapy simultaneously; the combination of fluconazole plus echinocandin has demonstrated synergistic activity against C. auris in vitro and is the recommended empirical approach in critically ill patients pending susceptibility data
D) Do not start fluconazole; Candida auris frequently displays pan-azole resistance — simultaneous resistance to fluconazole, voriconazole, itraconazole, and posaconazole — present at baseline independent of prior azole exposure, distinguishing it from Candida glabrata (variable acquired resistance) and Candida krusei (intrinsic fluconazole-only resistance); initiate an echinocandin empirically and obtain full susceptibility testing including azoles, echinocandins, and amphotericin B before making any definitive antifungal selection
E) Do not start any antifungal until formal susceptibility results are returned; Candida auris resistance is so unpredictable and variable that no empirical treatment choice is reliable, and premature initiation of any antifungal risks selecting for further resistance mutations before the optimal agent is identified
ANSWER: D
Rationale:
Option D is correct. Candida auris is a globally emerging multidrug-resistant pathogen with a resistance profile qualitatively distinct from the other azole-resistant Candida species. Unlike Candida glabrata, whose azole resistance is variable and partly acquired (10 to 30% resistant in most centers, enriched by prior azole exposure), and unlike Candida krusei, which has intrinsic resistance to fluconazole specifically but retains susceptibility to voriconazole, C. auris frequently displays pan-azole resistance — simultaneous high-level resistance to fluconazole, voriconazole, itraconazole, and posaconazole — present at baseline in many isolates without requiring prior antifungal exposure. Additionally, echinocandin resistance and amphotericin B resistance occur in a significant subset of C. auris isolates. This combination of multi-drug resistance makes C. auris uniquely dangerous in the ICU setting: empirical fluconazole — appropriate for many Candida species — is likely ineffective, and even echinocandin susceptibility cannot be assumed without testing. The correct approach is to initiate an echinocandin empirically (as echinocandins are the most reliable first-line choice given the pan-azole resistance profile), mandate full susceptibility testing of every isolate across all antifungal classes, and adjust therapy based on results. Additionally, C. auris outbreak control measures (contact precautions, environmental decontamination) must be implemented immediately given its propensity for healthcare-associated spread.
Option A: Option A is incorrect; C. auris does not share the resistance profile of C. glabrata. C. auris pan-azole resistance is typically present at baseline in many isolates, not in only 10 to 30%. Dose escalation to 800 mg fluconazole will not overcome the mechanism of pan-azole resistance.
Option B: Option B is incorrect; C. auris does not reliably retain fluconazole susceptibility in azole-naive patients. Pan-azole resistance in C. auris is frequently baseline and not dependent on prior azole exposure, making empirical fluconazole an unreliable choice.
Option C: Option C is incorrect; fluconazole plus echinocandin combination is not the established standard for C. auris. If the organism is pan-azole resistant, adding fluconazole to an echinocandin adds no antifungal benefit and unnecessarily exposes the patient to drug interactions and toxicity.
Option E: Option E is incorrect; withholding all antifungal therapy in a septic patient with candidemia while awaiting susceptibility results is not acceptable. Echinocandins represent the most reliable empirical choice for C. auris given its pan-azole resistance, and treatment should not be delayed — early appropriate antifungal therapy is associated with improved outcomes in candidemia.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.